New developments in the treatment of ovarian cancer-future perspectives

Annals of Oncology

Volumn 24, Issue SUPPL.10, 2013, Pages

  Lopez, J ^a   Banerjee, S ^a   Kaye, S B ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BMN 673; BRCA1 PROTEIN; BRCA2 PROTEIN; BRIVANIB; CEDIRANIB; CEP 9722; DOVITINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GP 1201; INO 1001; MM 121; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NINTEDANIB; NIRAPARIB; OLAPARIB; PACLITAXEL; PAZOPANIB; PF 0136738; PLACEBO; PLATINUM DERIVATIVE; REGN 421; SELUMETINIB; TAXANE DERIVATIVE; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VINTAFOLIDE;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; HUMAN; MULTIMODALITY CANCER THERAPY; OVARY CANCER; OVARY CARCINOMA; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BRCA1 PROTEIN; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; SIGNAL TRANSDUCTION;

EID: 84888209379     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt475     Document Type: Article

References (102)

1. Ferlay J, Shain H, Bray F et al. GLOBOCAN, GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide. IARC Cancerbase No, 10 [Internet] Lyon, France: International Agency for Research on Cancer; 2010; http://globocan.iarc. fr (May 2013, date last accessed).
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1): 11-30.
3. UK, C.R., Ovarian cancer-UK incidence statistics [online]; http://info. cancerresearchuk.org/cancerstats/types/ovary/incidence/(May 2013, date last accessed)
4. Cooke SL, Brenton JD et al. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 2011; 12(12): 1169-1174.
5. Galluzzi L, Senovilla L, Vitale I et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31(15): 1869-1883.
6. Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol 2010; 117(3): 429-439.
7. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol 2009; 40(9): 1213-1223.
8. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011; 43(5): 420-432.
9. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16(5): 267-282.
10. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474(7353): 609-615.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
12. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438 (7070): 932-936.
13. Schmitt J, Matei D. Targeting angiogenesis in ovarian cancer. Cancer Treat Rev 2012; 38(4): 272-283.
14. Paley PJ, Staskus KA, Gebhard K et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997; 80(1): 98-106.
15. Olson TA, Mohanraj D, Carson LF et al. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 1994; 54(1): 276-280.
16. Aghajanian C, Blank SV, GoffBA et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30(17): 2039-2045.
17. Pujade-Lauraine E et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2012; 30(18_suppl): LBA5002.
18. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365(26): 2473-2483.
19. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365(26): 2484-2496.
20. Monk BJ, Dalton H, Farley JH et al. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol/Hematol 2013; 86 (2): 161-175.
21. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8(8): 592-603.
22. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 2012; 30(32): 4026-4034.
23. Fernando NT, Koch M, Rothrock C et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008; 14(5): 1529-1539.
24. Moreno Garcia V, Basu B, Molife LR et al. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 2012; 18 (14): 3750-3761.
25. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013; 19(5): 961-968.
26. Gerald D, Chintharlapalli S, Augustin HG et al. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 2013; 73(6): 1649-1657.
27. Coxon A, Bready J, Min H et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010; 9 (10): 2641-2651.
28. Hashizume H, Falcon BL, Kuroda T et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70(6): 2213-2223.
29. Karlan BY, Oza AM, Richardson GE et al. Randomized, double-blind, placebocontrolled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012; 30(4): 362-371.
30. Kaye S et al. Brivanib in advanced ovarian cancer. Subset results of a phase II randomised discontinuation trial. Ann Oncol 2012; 23: 319.
31. Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 2011; 104 (3): 399-406.
32. Yan M, Plowman GD. Delta-like 4/notch signaling and its therapeutic implications. Clin Cancer Res 2007; 13(24): 7243-7246.
33. Lu C, Han HD, Mangala LS et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010; 18(2): 185-197.
34. Ahmed N, Abubaker K, Findlay J et al. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem 2013; 114 (1): 21-34.
35. Hu S, Yu L, Li Z et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 2010; 10 (8): 788-795.
36. Rizzo S, Hersey JM, Mellor P et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011; 10(2): 325-335.
37. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 2012; 22(1): 33-40.
38. Kulbe H, Chakravarty P, Leinster DA et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2012; 72 (1): 66-75.
39. Stone RL, Nick AM, McNeish IA et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012; 366(7): 610-618.
40. Coward J, Kulbe H, Chakravarty P et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17(18): 6083-6096.
41. Jubb AM, Oates AJ, Holden S et al. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006; 6(8): 626-635.
42. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010; 11(12): 1172-1183.
43. Lambrechts D, Lenz HJ, de Haas S et al. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013; 31(9): 1219-1230.
44. Jain RK, Duda DG, Clark JW et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3(1): 24-40.
45. O'Connor JP, Jackson A, Parker GJ et al. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 2012; 9(3): 167-177.
46. Dean E, Middleton MR, Pwint T et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012; 106(3): 468-474.
47. Curtin NJ. DNA Repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012; 12(12): 801-817.
48. Reed E. DNA Damage and repair in translational oncology: an overview. Clin Cancer Res 2010; 16(18): 4511-4516.
49. Tutt A, Bertwistle D, Valentine J et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 2001; 20(17): 4704-4716.
50. Cass I, Baldwin RL, Varkey T et al. Improved survival in women with BRCAassociated ovarian carcinoma. Cancer 2003; 97(9): 2187-2195.
51. Tan DS, Rothermundt C, Thomas K et al. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26(34): 5530-5536.
52. Martin SA, Lord CJ, Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008; 18(1): 80-86.
53. Brough R, Frankum JR, Costa-Cabral S et al. Searching for synthetic lethality in cancer. Curr Opin Genet Dev 2011; 21(1): 34-41.
54. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011; 105(8): 1114-1122.
55. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434 (7035): 913-917.
56. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917-921.
57. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361(2): 123-134.
58. Fong PC, Yap TA, Boss DS et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28(15): 2512-2519.
59. Audeh MW, Carmichael J, Penson RT et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376(9737): 245-251.
60. Kaye SB, Lubinski J, Matulonis U et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADPribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012; 30 (4): 372-379.
61. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95(1): 1-8.
62. Geisler JP, Hatterman-Zogg MA, Rathe JA et al. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002; 94(1): 61-67.
63. Pal T, Permuth-Wey J, Betts JA et al. BRCA1 And BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104(12): 2807-2816.
64. Risch HA, McLaughlin JR, Cole DE et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98(23): 1694-1706.
65. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12(9): 852-861.
66. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinumsensitive relapsed ovarian cancer. N Engl J Med 2012; 366(15): 1382-1392.
67. Ang JE, Gourley C, Powell CB et al. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of poly(ADP-ribose) polymerase inhibitor resistance: a multi-institutional study. Clin Cancer Res 2013; 19(9): 5485-5493.
68. Sandhu SK, Wenham RM, Wilding G et al. First -in-human trial of a PARP inhibitor MK4827 in advanced cancer patients with antitumour activity in BRCA deficient and sporadic ovarian cancer. ASCO Meeting Abstracts 2010;28:15s; (abst 3001).
69. Oza A, Cibula D. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): a randomized, open-label phase II study. J Clin Oncol, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2012; 30(15_suppl): 5001.
70. Edwards SL, Brough R, Lord CJ et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451(7182): 1111-1115.
71. Sakai W, Swisher EM, Karlan BY et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451(7182): 1116-1120.
72. Norquist B, Wurz KA, Pennil CC et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011; 29(22): 3008-3015.
73. Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105(44): 17079-17084.
74. Oplustilova L, Wolanin K, Mistrik M et al. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Cell Cycle 2012; 11(20): 3837-3850.
75. Do K, Chen A. Molecular pathways: targeting PARP in cancer treatment. Clin Cancer Res 2013; 19(5): 977-984.
76. Konstantinopoulos PA, Spentzos D, Karlan BY et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010; 28(22): 3555-3561.
77. O'Shannessy DJ, Somers EB, Smale R et al. Expression of folate receptor-alpha (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol 2013; 32(3): 258-268.
78. Lorusso PM, Edelman MJ, Bever SL et al. Phase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumors. J Clin Oncol 2012; 30(32): 4011-4016.
79. Naumann RW, Coleman RL, Burger RA et al. PRECEDENT: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. ASCO Meeting Abstracts, 2011; 29(15_suppl): p. 5045.
80. Singer G, Stohr R, Cope L et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29(2): 218-224.
81. Kurman RJ, Shih Ie M et al. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34(3): 433-443.
82. Singer G, Oldt R, 3rd, Cohen Y. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95(6): 484-486.
83. Diaz-Padilla I, Malpica AL, Minig L et al. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 2012; 126(2): 279-285.
84. Farley J, Brady WE, Vathipadiekal V et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013; 14(2): 134-140.
85. Hanrahan AJ, Schultz N, Westfal ML et al. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2012; 2(1): 56-67.
86. Weberpals JI, Koti M, Squire JA. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet 2011; 204(10): 525-535.
87. Kuo KT, Mao TL, Jones S et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174(5): 1597-1601.
88. Engelman JA. Targeting PI3 K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9(8): 550-562.
89. Courtney KD, Corcoran RB, Engelman JA. The PI3 K pathway as drug target in human cancer. J Clin Oncol 2010; 28(6): 1075-1083.
90. Carden CP, Stewart A, Thavasu P et al. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther 2012; 11(7): 1609-1617.
91. Abedini MR, Muller EJ, Bergeron R et al. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 2010; 29(1): 11-25.
92. Yang X, Fraser M, Moll UM et al. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006; 66(6): 3126-3136.
93. Siwak DR, Carey M, Hennessy BT et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010; 2010: 568938.
94. Anglesio MS, Kommoss S, Tolche MC et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 2013; 229(1): 111-120.
95. Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res 2005; 11(15): 5539-5548.
96. Bookman MA, Darcy KM, Clarke-Pearson D et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21(2): 283-290.
97. Gordon MS, Matei D, Aghajanian C et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006; 24 (26): 4324-4332.
98. Agus DB, Gordon MS, Taylor C. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23 (11): 2534-2543.
99. Campbell MR, Amin D, Moasser MM et al. HER3 Comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 2010; 16(5): 1373-1383.
100. Tanner B, Hasenclever D, Stern K et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 2006; 24(26): 4317-4323.
101. Zhang X, Gureasko J, Shen K et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125(6): 1137-1149.
102. Sheng Q, Liu X, Fleming E et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010; 17(3): 298-310.